Ramzi Amri
Chief Financial Officer Oncoinvent AS
Ramzi Amri, MD, PhD, is Chief Financial Officer at Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing alpha therapies to prevent peritoneal metastases. He is responsible for finance, business development, and co-leads strategy, supporting the company’s clinical development and partnering activities. Prior to joining Oncoinvent, he held senior leadership roles at Galapagos, where he led development strategy and portfolio execution. Earlier in his career, he worked at McKinsey & Company advising healthcare and life sciences organizations on strategy, corporate finance, operations, and transformation. Dr. Amri trained as a physician at the University of Amsterdam and conducted his PhD and postdoctoral research at Harvard Medical School and Massachusetts General Hospital.
Seminars
Join your colleagues for a deep-dive discussion in smaller groups to map out the next generation of TRP targets. You will brainstorm high-potential clinical candidates and cross-pollinate ideas from the ADC space to sharpen selection strategy before sharing your table’s thoughts and discussion back to the group.
- Identifying optimal tumor targets by evaluating density, internalization, and off-target risk
- Exploring current targets under development and their potential clinical impact
- Applying lessons from antibody-drug conjugates and other targeted therapies to guide RLT target selection
- Limitations of systemic radioligand therapies in addressing microscopic peritoneal disease
- Scientific and clinical rationale for intraperitoneal delivery of alpha-emitting radiopharmaceuticals
- Development strategy for Radspherin® targeting prevention of peritoneal recurrence following surgery
